• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cornea >The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
【24h】

The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.

机译：结膜下联合贝伐单抗联合曲安奈德治疗兔角膜新生血管的作用。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE:: To evaluate the effect of subconjunctival combined treatment of bevacizumab and triamcinolone on corneal neovascularization in rabbits. METHODS:: Corneal neovascularization was induced by placing a suture at the both eyes of 15 rabbits. After the suture removal, rabbits were divided into 3 groups. The right eyes in group 1 (n = 5) were administered a subconjunctival injection of both bevacizumab and triamcinolone. The right eyes in group 2 (n = 5) and group 3 (n = 5) had bevacizumab and triamcinolone, respectively. The left eyes in 3 groups (n = 15) were used as controls. Two weeks later, digital photographs were taken and analyzed to determine the area of corneal neovascularization. The level of vascular endothelial growth factor (VEGF) and interleukin (IL)-6 in corneal tissue were measured. RESULTS:: Analysis of digital photographs showed that there was less corneal neovascularization in three groups than in control (P < 0.001). The area of corneal neovascularization in groups 1 and 2 was less than in group 3 (P = 0.027 between groups 1 and 3, P = 0.045 between groups 2 and 3). The concentrations of VEGF and IL-6 were significantly lower in 3 groups than in control (P < 0.001, P = 0.023). The level of VEGF in groups 1 and 2 was less than in group 3 (P = 0.009 between groups 1 and 3, P = 0.045 between groups 2 and 3). For IL-6, there was no intergroup difference. CONCLUSION:: Combined treatment with both bevacizumab and triamcinolone showed significant regression of corneal neovascularzation. However, combined treatment failed to show significant superiority in the treatment of corneal neovascularization, compared to bevacizumab therapy alone.
机译：目的：评价结膜下联合贝伐单抗和曲安奈德治疗兔角膜新生血管的作用。方法：通过在15只兔的双眼处缝合缝合线诱导角膜新生血管形成。去除缝线后，将兔子分成3组。在第1组（n = 5）的右眼进行了贝伐单抗和曲安奈德的结膜下注射。第2组（n = 5）和第3组（n = 5）的右眼分别具有贝伐单抗和曲安奈德。 3组（n = 15）的左眼用作对照。两周后，拍摄了数码照片并进行了分析，以确定角膜新生血管的面积。测量角膜组织中血管内皮生长因子（VEGF）和白介素（IL）-6的水平。结果：数码照片的分析显示，三组角膜新生血管的数量少于对照组（P <0.001）。第1和第2组的角膜新生血管面积小于第3组（第1和第3组之间的P = 0.027，第2和第3组之间的P = 0.045）。 3组中VEGF和IL-6的浓度显着低于对照组（P <0.001，P = 0.023）。第1组和第2组的VEGF水平低于第3组（第1组和第3组之间的P = 0.009，第2组和第3组之间的P = 0.045）。对于IL-6，组间无差异。结论：贝伐单抗和曲安奈德联合治疗显示角膜新生血管明显消退。然而，与单独的贝伐单抗治疗相比，联合治疗在角膜新生血管治疗中没有显示出明显的优势。

著录项

  • 来源
    《Cornea》 |2010年第2期|共5页
  • 作者

    Kang S; Chung SK;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 眼科学;
  • 关键词

  • 入库时间 2022-08-18 09:43:31

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号